Judy Chiao
CIK 1357601 · View on SEC EDGAR ↗
First SEC filing: March 29, 2006 · Latest: Feb. 17, 2015
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 9, 2008 | BGMS | P | 1,000 | $2.14 | $2,140 | 48,168 Direct | +2.12% | Acquired | -100.0% (price as of 2026-08-21) |
| June 9, 2008 | BGMS | P | 38 | $2.13 | $81 | 47,168 Direct | +0.08% | Acquired | -100.0% (price as of 2026-08-21) |
| June 9, 2008 | BGMS | P | 362 | $2.14 | $775 | 47,130 Direct | +0.77% | Acquired | -100.0% (price as of 2026-08-21) |
| June 9, 2008 | BGMS | P | 400 | $2.13 | $852 | 46,768 Direct | +0.86% | Acquired | -100.0% (price as of 2026-08-21) |
| June 9, 2008 | BGMS | P | 100 | $2.14 | $214 | 46,368 Direct | +0.22% | Acquired | -100.0% (price as of 2026-08-21) |
| June 9, 2008 | BGMS | P | 100 | $2.11 | $211 | 46,268 Direct | +0.22% | Acquired | -100.0% (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Dec. 5, 2019 | BGMS | Option | Common Stock (10,182) | $1.56 | Feb. 22, 2028 | 10,182 | Acquired |
| Dec. 5, 2019 | BGMS | Option | Common Stock (11,067) | $1.74 | Dec. 29, 2027 | 11,067 | Acquired |
| Jan. 4, 2019 | BGMS | Option | Common Stock (284,592) | $0.71 | Jan. 4, 2029 | 284,592 | Acquired |
| Jan. 3, 2019 | BGMS | Option | Common Stock (10,183) | $1.56 | Feb. 22, 2028 | 10,183 | Acquired |
| Jan. 3, 2019 | BGMS | Option | Common Stock (11,068) | $1.74 | Dec. 29, 2027 | 11,068 | Acquired |
| Dec. 9, 2013 | BGMS | Option | Common Stock (65,000) | $4.61 | Dec. 9, 2023 | 65,000 | Acquired |
| Dec. 10, 2010 | BGMS | Option | Common Stock (62,500) | $1.59 | Dec. 10, 2020 | 62,500 | Acquired |
| Nov. 18, 2008 | BGMS | Option | Common Stock (75,000) | $0.44 | Nov. 18, 2018 | 75,000 | Acquired |
| Nov. 18, 2008 | BGMS | Restricted Stock Units | Common Stock (25,000) | — | — | 25,000 | Acquired |
| Nov. 18, 2008 | BGMS | Option | Common Stock (75,000) | $0.44 | Nov. 18, 2018 | 75,000 | Acquired |
| Dec. 6, 2007 | BGMS | Option | Common Stock (100,000) | $5.53 | Dec. 6, 2017 | 100,000 | Acquired |
| Dec. 21, 2006 | BGMS | Option | Common Stock (80,000) | $6.95 | Dec. 20, 2016 | 80,000 | Acquired |
| June 14, 2006 | BGMS | Common Stock Option | Common Stock (48,967) | $6.40 | June 14, 2016 | 48,967 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 2 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
BGMS
MD Vice President, Clinical Development and Regulatory Affairs| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2018 | $371,389 | $67,073 | — | $41,854 | — | — | $49,417 | $529,733 |
| 2017 | $371,389 | $103,989 | — | $15,914 | — | — | $46,867 | $538,159 |
| 2016 | $360,572 | $93,749 | — | $0 | — | — | $30,455 | $484,776 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.